JMP Securities initiated coverage of Vigil Neuroscience (NASDAQ:VIGL) with a “market outperform” rating and price target of $23. The stock was quoted at $6.50 midday on Oct 18. Vigil is developing novel therapies for...
JMP Securities initiated coverage of Pardes Biosciences (NASDAQ:PRDS) with a “market outperform” rating and price target of $9. The stock closed at $1.15 on Dec. 12. Pardes is developing PBI-0451 as a potential novel...
JMP Securities initiated coverage of iBio (NYSE American:IBIO) with a “market outperform” rating and price target of $1.50. The stock closed at 85 cents, up 19 cents, or 29%, on Nov. 29. iBio is a technology...